Chronic Myelomonocytic Leukemia (CMML) Recruiting Phase 1 Trials for Lenzilumab (DB15148)

IndicationStatusPhase
DBCOND0037697 (Chronic Myelomonocytic Leukemia (CMML))Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02546284Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)Treatment